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INTRODUCTION
umor angiogenesis is defined as the formation of neovessels
from preexisting vascular structures, mainly capillary and
venules, under the influence of a malignant tumor (1,2). In 1971,
Folkman reported that angiogenesis is mediated by angiogenic
molecules, inducing the growth of a close capillary network that
surrounds and invades tumors (3,4). This hypothesis has been
supported by indirect and direct evidence from many studies (5,8).
Angiogenesis are stimulated by the balance of stimulators vascu-
lar endothelial growth factor (VEGF), basic fibroblast growth fac-
tor (bFGF), and transforming growth factor, and eicosanoids syn-
thesized from n-6 fatty acids and inhibitors of angiogenesis (e.g.,
angiostatin, endostatin, angiostatic steroids) (9,10).
The "angiogenic switch" and tumor angiogenesis play a critical
role in the growth and metastasis of solid tumors. The stimulation
of angiogenesis during carcinogenesis is the result of the rupture
of the balance between pro- and anti-angiogenic factors. This rup-
ture may be due to the overexpression of angiogenic factors or the
loss of local anti-angiogenic factors (11,12). Recent studies show
the importance of tumor angiogenesis as an essential factor that
affects survival rate and malignant potential of some gynecologi-
cal malignant tumors. The importance of angiogenesis in gyneco-
logical oncology is as follows (13-19):
1) Intratumoral vessel density is an indicator for the emergence
and growth of malignant tumors and their precursor lesions, 
2) Intratumoral vessel density is an independent prognostic factor
for solid malignancies and
3)  The inhibition of tumor angiogenesis by means of anti-angio-
genetic substances causes suppression of tumor growth.
ANGIOGENESIS IN ENDOMETRIAL CANCER
Angiogenesis plays an important role in the regulation of the
female menstrual cycle. That important role is especially
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Increasing importance is given to the clinical significance of the new formation of vessels
(angiogenesis) in the course of physiological, inflammatory and neoplastic processes.
Angiogenesis is best studied in the growth of malignant tumors, since cancer may be
regarded as the most important angiogenesis-dependent disease. Vascular endothelial
cell proliferation, migration, and capillary formation are stimulated by angiogenic growth
factors, which include the proteins vascular endothelial growth factor (VEGF), basic
fibroblast growth factor (bFGF), and transforming growth factor, and eicosanoids synthe-
sized from n-6 fatty acids. Angiogenesis plays an important role in physiological prolifer-
ation of the endometrium and formation of corpus luteum in the second half of menstru-
al cycle. The present study showed that microvessel counts affect prognosis of patients
with endometrial cancer. Analysis of angiogenesis in endometrial cancer may be a useful
biologic parameter and additional study of neovascularization is required. Tumor angio-
genesis is regulated by the balance of stimulators (e.g., VEGF, bFGF) and inhibitors of
angiogenesis (e.g., angiostatin, endostatin, angiostatic steroids). Measuring angiogene-
sis (blood vessel density) and/or its main regulators such as VEGF and bFGF in solid
tumors, or the levels of these growth factors in the serum or urine provides new and sen-
sitive markers for tumor progression, metastasis and prognosis.
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2expressed during the second half of menstrual cycle.
The function of angiogenetic factors in the emergence of
endometriosis and in female and male infertility is currently under
study. In obstetrics, the new formation of blood vessels is signif-
icant for the implantation of impregnated blastocysts and for the
development and growth of the placenta (20).
Neoangiogenesis in endometrial cancer seems to have important
influence on prognosis of patients. 
First reports found that high microvessel counts had adverse
effect on prognosis in patients with endometrial cancer (21-23).
Mazurek et al. found statistically significant differences in total
angiogenic points’ density between groups of various clinical
FIGO staging, specifically between Ia and Ib, Ic, II. A positive cor-
relation was found between the clinical stage of the disease
(according to FIGO) and the total angiogenic points’ density, den-
sity of endothelial cells and the density of vessels with viable
lumen (counts/sq. mm calculated from the central parts of the
tumor) (24).
Capillary density in recurrent endometrial cancer also showed
neoengiogenesis as factor that correlates with survival. Among
patients with recurrent disease, those with a low capillary count
had mean survival of 64 months. Patients with recurrent disease
with tumors of high capillary density had a mean survival of 45
months (p = 0.002) (23).
Obermair et al. show that high intratumor microvessels count is
associated with poor survival (25).  
Seki N, et al. provide evidence that the expression vascular
endothelial growth factor (VEGF) and platelet-derived endothelial
cell growth factor (PD-ECGF) are involved in the promotion of
angiogenesis in endometrial cancer. In addition, VEGF and PD-
ECGF might contribute to the aggressive potential of low-grade
tumors or certain histological subtypes with unfavorable progno-
sis through the induction of angiogenesis (26).
Selvesen et al. reported a 5-year survival probability rates of 57%
and 90% for patients with high and low microvessel counts, and
in contrast Wagatsuma et al. reported a 0% survival rate in
patients with high microvessel counts (27,28).
In endometrial cancer the mean microvessel count per mm2
varies from 77/mm2 to 842/mm2 when sections were stained for
factor VIII-related antigen and enumerated at 400X magnification
(21,22).
A highly sensitive and reliable antigen for highlighting vascular
endothelial cells is CD34 (29).  By using this marker Obermair et
al. found a median microvessel count of 72/mm2 in patients with
stage I-III endometrial carcinoma. For 5 years, the overall survival
probability was 82.2% (+/- 7.6) in 69 patients whose tumors had
microvessel counts at or below 100/field, and 52.0%( +/- 13.2)
in 24 patients whose primary tumors had microvessel counts
above 100/field (p=0.004) (25).
Hashimoto et al. reported an influence of tumor- associated
macrophages (TAMs) in microvessel density and count. TAMs
infiltration was significantly high in tumors with deep myometrial
invasion, high grade and elderly patients. Microvessel count
strongly correlated with TAMs in tumor stroma (p=0.0002).
However, associated macrophages may play a crucial role in the
promotion of angiogenesis, but cannot be used to predict prog-
nosis of patients with endometrial cancer (30).
Ishiwata I, et al. reported tumor angiogenic activity from tumor
angiogenesis factors (TAFs) produced by 25 cell lines that was
assayed onto chorioallantoic membranes (CAMs).
Neovascularization occurred prominently in such cell lines, as
HTBOA (poorly differentiated ovarian carcinoma), HUOCA-II
(poorly differentiated clear cell adenocarcinoma), HWUA (poorly
differentiated endometrial adenocarcinoma), HKUS (uterine cervi-
cal small cell carcinoma), and in HOTHC (anaplastic thyroid car-
cinoma). The cell lines that secreted TAF showed high hetero-
transplantability in nude mice and produced rapidly growing
tumors, which were rich in blood vessels (31).
The study of tumor angiogenesis is currently one of the leading
themes in oncology. This is justified by the importance of tumor
angiogenesis in the natural history of cancer, the possible appli-
cations of angiogenesis markers as prognostic factors and the
emergence of innovative anti-tumor treatments based on anti-
angiogenic strategies.
Tumor angiogenesis is not specific for one type of tumor and
angiogenetic factors of growth cannot be specific for one type of
malignant disease.  It is a process that has the major role in devel-
oping of many types of tumors and metastasis.
Immunohistochemical studies showed importance of angiogenic
factors and microvessel density in other cancers such as breast
cancer, gastrointestinal cancers, soft-tissue sarcoma and others
(32-37).
CONCLUSION
Tumor angiogenesis is one of the important events in the natural
history of cancer. Applications of angiogenesis markers as prog-
nostic factors and investigation of anti-tumor treatments based on
anti-angiogenic strategies as new type of anti-cancer therapy lead
us to the new goals in oncology today.
Proliferation of the endometrium and the formation of the corpus
luteum in the second half of the menstrual cycle are examples of
angiogenesis in the physiological field.
Neoangiogenesis appear to be important factor in development of
endometrial cancer.
High microvessel counts in endometrial carcinoma means poor
prognostic factor and decrease in survival rate.
Mandi￿ A.
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